Citius Pharmaceuticals (NASDAQ:CTXR) Announces Quarterly Earnings Results

Posted by Ethan Ryder on Feb 15th, 2025

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) posted its earnings results on Friday. The company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($1.25) by ($0.05), Zacks reports.

Citius Pharmaceuticals Stock Performance

Shares of CTXR opened at $2.69 on Friday. Citius Pharmaceuticals has a 1 year low of $2.44 and a 1 year high of $26.75. The business has a 50-day moving average of $3.17 and a 200-day moving average of $8.85.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CTXR. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Citius Pharmaceuticals in a research report on Tuesday, January 7th.

Check Out Our Latest Stock Analysis on CTXR

Citius Pharmaceuticals Company Profile

(Get Free Report)

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.